

Mitchell R Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7864952/publications.pdf>

Version: 2024-02-01

139
papers

8,450
citations

109311

35
h-index

46795

89
g-index

139
all docs

139
docs citations

139
times ranked

10773
citing authors

#	ARTICLE	IF	CITATIONS
1	Axicabtagene Ciloleucef CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	27.0	3,865
2	Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. <i>Oncogene</i> , 2003, 22, 7359-7368.	5.9	690
3	Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2085-2093.	1.6	306
4	Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. <i>Blood</i> , 2012, 119, 4597-4607.	1.4	278
5	Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. <i>Journal of Clinical Oncology</i> , 2014, 32, 1242-1248.	1.6	227
6	Utilization of fine-needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma. <i>Cancer</i> , 1998, 84, 252-261.	4.1	154
7	Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. <i>Journal of Clinical Oncology</i> , 2013, 31, 573-583.	1.6	142
8	Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2008, 143, 355-360.	2.5	93
9	Novel Protein Disulfide Isomerase Inhibitor with Anticancer Activity in Multiple Myeloma. <i>Cancer Research</i> , 2016, 76, 3340-3350.	0.9	90
10	Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Journal of Clinical Oncology</i> , 2012, 30, 3119-3126.	1.6	86
11	Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin's Lymphoma Resulting in Durable Clinical Responses. <i>Journal of Clinical Oncology</i> , 2006, 24, 3107-3112.	1.6	85
12	Immunotherapy of cancer. <i>European Journal of Pharmacology</i> , 2009, 625, 41-54.	3.5	85
13	Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. <i>British Journal of Haematology</i> , 2015, 168, 765-768.	2.5	75
14	A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. <i>Leukemia and Lymphoma</i> , 2013, 54, 1373-1379.	1.3	65
15	Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. <i>British Journal of Haematology</i> , 2016, 172, 384-391.	2.5	63
16	Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγR3a-Genotyped Patients with Previously Treated Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 1395-1403.	7.0	61
17	Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). <i>Blood</i> , 2014, 123, 1665-1673.	1.4	61
18	Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells. <i>Oncotarget</i> , 2016, 7, 70000-70010.	1.8	59

#	ARTICLE	IF	CITATIONS
19	A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2. <i>Oncotarget</i> , 2015, 6, 27388-27402.	1.8	59
20	Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines. <i>Clinical Cancer Research</i> , 2009, 15, 2808-2817.	7.0	54
21	Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics. <i>Oncotarget</i> , 2015, 6, 16912-16925.	1.8	53
22	Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. <i>Blood</i> , 2011, 118, 3525-3527.	1.4	49
23	Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine1. <i>Academic Radiology</i> , 2004, 11, 368-376.	2.5	48
24	NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. <i>Oncolmmunology</i> , 2017, 6, e1330235.	4.6	47
25	Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. <i>Leukemia and Lymphoma</i> , 2017, 58, 1607-1616.	1.3	46
26	Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 5809-5816.	7.0	45
27	A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). <i>Cancer Genetics and Cytogenetics</i> , 1993, 70, 62-67.	1.0	44
28	miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies. <i>Molecular Cancer</i> , 2015, 14, 185.	19.2	42
29	Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2005, 106, 489-489.	1.4	42
30	Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: Report of two cases and review of the literature. <i>Leukemia Research</i> , 2006, 30, 109-114.	0.8	41
31	Quantitative electrophoretic transfer of DNA from polyacrylamide or agarose gels to nitrocellulose. <i>Analytical Biochemistry</i> , 1984, 137, 120-124.	2.4	40
32	Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies. <i>Cancer Research</i> , 2007, 67, 8923-8931.	0.9	40
33	Cutaneous Precursor B-Cell Lymphoblastic Lymphoma in 2 Adult Patients. <i>Archives of Dermatology</i> , 2008, 144, 1155-62.	1.4	40
34	Mantle cell lymphoma: advances in biology and therapy. <i>Current Opinion in Hematology</i> , 2008, 15, 415-421.	2.5	40
35	Bortezomib Sensitizes Non-Hodgkin's Lymphoma Cells to Apoptosis Induced by Antibodies to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Receptors TRAIL-R1 and TRAIL-R2. <i>Clinical Cancer Research</i> , 2007, 13, 5528s-5534s.	7.0	38
36	An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 215-222.	2.5	35

#	ARTICLE	IF	CITATIONS
37	Phase II Study of R-CHOP Followed by 90Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Blood</i> , 2007, 110, 389-389.	1.4	35
38	The Value of Transformed Lymphocyte Count in Subclassification of Non-Hodgkin's Lymphoma by Fine-Needle Aspiration. <i>American Journal of Clinical Pathology</i> , 1997, 108, 143-151.	0.7	34
39	Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. <i>Leukemia Research</i> , 2013, 37, 1213-1215.	0.8	34
40	Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 989-996.	4.1	33
41	Comparison of the prognostic utility of the revised International Prognostic Scoring System and the <i>International Prognostic Scoring System</i> in azacitidine-treated patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2014, 166, 352-359.	2.5	31
42	Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 250-256.	2.5	30
43	Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγR3a Patients with Previously Treated Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 42-48.	1.3	29
44	Ibrutinib in B lymphoid malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1879-1887.	1.8	28
45	Phosphomonoester concentrations differ between chronic lymphocytic leukemia cells and normal human lymphocytes. <i>Leukemia Research</i> , 2002, 26, 919-926.	0.8	27
46	Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. <i>Leukemia and Lymphoma</i> , 2006, 47, 1902-1907.	1.3	27
47	Dose Dependent Effects on Cell Cycle Checkpoints and DNA Repair by Bendamustine. <i>PLoS ONE</i> , 2012, 7, e40342.	2.5	27
48	Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised <i>IPSS</i> . <i>British Journal of Haematology</i> , 2014, 167, 62-68.	2.5	27
49	Clinical approach to diffuse large B cell lymphoma. <i>Blood Reviews</i> , 2016, 30, 477-491.	5.7	26
50	Extranodal NK/T-cell lymphoma nasal type: Efficacy of pegaspargase. Report of two patients from the United States and review of literature. <i>Leukemia Research</i> , 2010, 34, e50-e54.	0.8	25
51	Clonal evolution of chronic lymphocytic leukemia to acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1996, 86, 143-146.	1.0	22
52	Dexamethasone plus retinoids decrease <i>IL6/IL6</i> receptor and induce apoptosis in myeloma cells. <i>British Journal of Haematology</i> , 1998, 102, 1090-1097.	2.5	22
53	Targeting mTORC1-Mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells. <i>Molecular Cancer Research</i> , 2014, 12, 1205-1215.	3.4	22
54	Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions. <i>Cancer Biology and Therapy</i> , 2015, 16, 1397-1406.	3.4	22

#	ARTICLE	IF	CITATIONS
55	Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice. <i>BMC Cancer</i> , 2005, 5, 103.	2.6	20
56	Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. <i>PLoS ONE</i> , 2017, 12, e0172996.	2.5	20
57	Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study. <i>Blood</i> , 2008, 112, 266-266.	1.4	20
58	Contribution of Flow Cytometry in the Diagnosis of Cutaneous Lymphoid Lesions. <i>Journal of Investigative Dermatology</i> , 2003, 121, 1522-1530.	0.7	19
59	Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis. <i>Blood Advances</i> , 2021, 5, 2863-2878.	5.2	19
60	Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or 'Aggressive' Lymphoma.. <i>Blood</i> , 2009, 114, 584-584.	1.4	19
61	Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 1693-9.	4.1	19
62	Bacteremia and Suppurative Lymphadenitis Due to <i>Yersinia enterocolitica</i> in a Neutropenic Patient Who Prepared Chitterlings. <i>Clinical Infectious Diseases</i> , 1995, 21, 236-237.	5.8	18
63	Pediatric nodal marginal zone lymphoma may develop in the adult population. <i>Leukemia and Lymphoma</i> , 2010, 51, 89-94.	1.3	18
64	Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.. <i>Blood</i> , 2006, 108, 2711-2711.	1.4	18
65	Stat3 Inhibition Augments the Immunogenicity of B-cell Lymphoma Cells, Leading to Effective Antitumor Immunity. <i>Cancer Research</i> , 2012, 72, 4440-4448.	0.9	17
66	Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. <i>British Journal of Haematology</i> , 2014, 166, 514-520.	2.5	17
67	CCMCL1: a new model of aggressive mantle cell lymphoma. <i>Blood</i> , 2015, 125, 2730-2732.	1.4	17
68	Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 55.	3.0	17
69	Prothymosin $\hat{\pm}$: in Search of a Function. <i>Leukemia and Lymphoma</i> , 1995, 18, 209-214.	1.3	16
70	Role of ubiquitin carboxyl terminal hydrolase in the differentiation of human acute lymphoblastic leukemia cell line, Reh. <i>Differentiation</i> , 1996, 60, 59-66.	1.9	16
71	Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEP system. <i>British Journal of Haematology</i> , 2014, 167, 281-285.	2.5	16
72	Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. <i>British Journal of Haematology</i> , 2016, 175, 275-280.	2.5	16

#	ARTICLE	IF	CITATIONS
73	Radioimmunotherapy in mantle cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 201-210.	1.7	15
74	Non-Hodgkin's lymphoma. <i>Current Problems in Cancer</i> , 1996, 20, 6-77.	2.0	14
75	Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 83-88.	0.4	14
76	Nucleosome arrangement in $\hat{\pm}$ -satellite chromatin of African green monkey cells. <i>Nucleic Acids Research</i> , 1984, 12, 6493-6510.	14.5	13
77	Early Generated B-1â€œDerived B Cells Have the Capacity To Progress To Become Mantle Cell Lymphomaâ€œlike Neoplasia in Aged Mice. <i>Journal of Immunology</i> , 2018, 201, 804-813.	0.8	13
78	Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)., <i>Blood</i> , 2011, 118, 3904-3904.	1.4	13
79	Ionizing radiation exposures in treatments of solid neoplasms are not associated with subsequent increased risks of chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2016, 43, 9-12.	0.8	12
80	Dual institution experience of extranodal marginal zone lymphoma reveals excellent longâ€œterm outcomes. <i>British Journal of Haematology</i> , 2016, 173, 404-412.	2.5	12
81	CD30 Immunohistochemical Expression In Diffuse Large B-Cell Lymphoma Is Associated With Decreased Overall Survival and The Non-Germinal Center Molecular Subtype. <i>Blood</i> , 2013, 122, 4318-4318.	1.4	12
82	A human b-cell lymphoma line with a de novo multidrug resistance phenotype. <i>Cancer</i> , 1992, 69, 1468-1474.	4.1	11
83	A phase 1 doseâ€œescalation study of XmAb^{Â®}2513 in patients with relapsed or refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 902-904.	2.5	11
84	Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era. <i>Hematology</i> , 2017, 22, 405-411.	1.5	11
85	Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2018, 59, 1195-1201.	1.3	11
86	Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw263.	6.3	10
87	Should there be a standard therapy for mantle cell lymphoma?. <i>Future Oncology</i> , 2011, 7, 227-237.	2.4	9
88	Brentuximab vedotin in anaplastic large cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 633-639.	3.1	9
89	Noninvasive Phosphorus Magnetic Resonance Spectroscopic Imaging Predicts Outcome to First-line Chemotherapy in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma. <i>Academic Radiology</i> , 2013, 20, 1122-1129.	2.5	9
90	The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 â€œ A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.. <i>Blood</i> , 2009, 114, 1661-1661.	1.4	9

#	ARTICLE	IF	CITATIONS
91	Continuous infusion ABDC therapy for relapsed or refractory Hodgkin's disease. <i>Cancer</i> , 1994, 73, 1264-1269.	4.1	8
92	Management of mantle cell lymphoma in the elderly. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 221-231.	1.7	8
93	Milatumuzab and veltuzumab induce apoptosis through JNK signalling in an NF- κ B dependent human transformed follicular lymphoma cell line. <i>British Journal of Haematology</i> , 2014, 165, 151-153.	2.5	8
94	Urea reduces the thermal stability of polyanion-treated chromatin. <i>Biochemical and Biophysical Research Communications</i> , 1977, 74, 1475-1482.	2.1	7
95	Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of 18 F-NaF PET scan in treatment planning. <i>British Journal of Haematology</i> , 2017, 179, 674-676.	2.5	7
96	Antisense oligonucleotides complementary to immunoglobulin sequences of BCL-2/immunoglobulin fusion transcript induce apoptosis of t(14;18) lymphoma cells. <i>British Journal of Haematology</i> , 2000, 111, 1087-1092.	2.5	7
97	Immune Cell Dysfunction in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2012, 120, 3875-3875.	1.4	7
98	Altered Levels of Prothymosin Immunoreactive Peptide, a Growth-Related Gene Product, During Liver Regeneration after Chronic Ethanol Feeding. <i>Alcoholism: Clinical and Experimental Research</i> , 1994, 18, 616-619.	2.4	6
99	Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. <i>Cancer</i> , 2004, 101, 2034-2041.	4.1	6
100	Is Early Hematopoietic Stem-Cell Transplantation Necessary in Mantle-Cell Lymphoma?. <i>Journal of Clinical Oncology</i> , 2014, 32, 265-267.	1.6	6
101	Role of Huntingtin Interacting Protein HIP-1 in Non-Hodgkin's Lymphoma. <i>Blood</i> , 2006, 108, 2384-2384.	1.4	5
102	Coexisting myelodysplasia and myeloproliferative features in a single clone containing 5q-, Ph and i(17q). <i>Leukemia Research</i> , 1999, 23, 965-967.	0.8	4
103	Tetanus toxoid reactive lymphadenopathy masquerading as T-cell lymphoma. <i>Future Oncology</i> , 2012, 8, 631-634.	2.4	4
104	Utilization of fine needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma. <i>Cancer</i> , 1998, 84, 252-261.	4.1	4
105	Role of Different Frontline Regimens in Achieving Complete Response in Follicular Lymphoma: A Meta-Analysis of CR Rate and Its Relation to Hazard Rate for Disease Progression. <i>Blood</i> , 2006, 108, 2754-2754.	1.4	4
106	Parametric Model of Combination Therapy for Non-Hodgkin Lymphoma. <i>PLoS ONE</i> , 2012, 7, e51736.	2.5	4
107	Antisense oligonucleotides complementary to immunoglobulin sequences of BCL-2/immunoglobulin fusion transcript induce apoptosis of t(14;18) lymphoma cells. <i>British Journal of Haematology</i> , 2000, 111, 1087-1092.	2.5	3
108	Phase II Study of PENDING Chemotherapy in Patients with Refractory/Relapsed Hodgkin Lymphoma. <i>Leukemia and Lymphoma</i> , 2004, 45, 2079-2084.	1.3	3

#	ARTICLE	IF	CITATIONS
109	Antibodies and Hematologic Malignancies. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 184-190.	2.0	3
110	Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Seminars in Oncology</i> , 2010, 37, 183-187.	2.2	3
111	Progression and Transformation of Clonally Heterogeneous B-cell Lymphoma. <i>PLoS ONE</i> , 2015, 10, e0130590.	2.5	3
112	Emergence of myeloid stem cell line from T-lymphoid blastic phase of chronic myeloid leukemia in culture. <i>Leukemia Research</i> , 1992, 16, 521-527.	0.8	2
113	Treatment-Related Myelodysplastic Syndrome Following Abdominopelvic Radiotherapy for Endometrial Cancer. <i>Gynecologic Oncology</i> , 1995, 57, 430-432.	1.4	2
114	Thymosin $\alpha 1$ does not promote growth or oncogenic transformation. <i>International Journal of Immunopharmacology</i> , 1996, 18, 321-327.	1.1	2
115	Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation. <i>Stem Cells and Cloning: Advances and Applications</i> , 2010, 3, 93.	2.3	2
116	Prediction and Early Detection of Response by NMR Spectroscopy and Imaging. <i>PET Clinics</i> , 2012, 7, 119-126.	3.0	2
117	A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib. <i>Blood</i> , 2016, 128, 1115-1115.	1.4	2
118	Once Weekly Subcutaneous Bortezomib, Cyclophosphamide, and Dexamethasone As Induction Therapy for All AL Amyloidosis. <i>Blood</i> , 2016, 128, 5813-5813.	1.4	2
119	New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals. <i>Discoveries</i> , 2014, 2, e14.	2.3	2
120	Lacrimal gland lymphoma: Role of radiation therapy. <i>Oman Journal of Ophthalmology</i> , 2012, 5, 37.	0.3	1
121	Bortezomib for the treatment of mantle cell lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1233-1241.	0.8	1
122	Ibrutinib: a force with a dark side?. <i>Blood</i> , 2016, 127, 1523-1524.	1.4	1
123	Optimal use of novel agents in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2018, 70, 37-40.	0.8	1
124	Peripheral Blood CD3+CD4+ and CD3+CD56+ Cell Counts and Circulating Lymphoma Cells Are Significant Predictors of Overall Survival in Newly Diagnosed Follicular Lymphoma.. <i>Blood</i> , 2007, 110, 2607-2607.	1.4	1
125	Comment on "Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study," by Kahl et al., <i>Cancer Investigation</i> , 2005, 23(1), pp. 13-18. <i>Cancer Investigation</i> , 2005, 23, 572-572.	1.3	0
126	Allogeneic Transplantation for Lymphoma: Risk-Benefit Balance Is in the Eye of the Beholder. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 905-906.	2.0	0

#	ARTICLE	IF	CITATIONS
127	Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture. <i>Leukemia Research</i> , 2021, 110, 106663.	0.8	0
128	Development of B Cell Lymphoma in E1/4-Cyclin D1 X Mutant p53 Transgenic Mice.. <i>Blood</i> , 2005, 106, 1907-1907.	1.4	0
129	Vinblastine, Mitoxantrone and Prednisone (MVP) Followed by Involved Field Radiotherapy (IF-XRT) for Early Clinical Stage Hodgkins's Lymphoma: Long Term Follow-Up.. <i>Blood</i> , 2005, 106, 2677-2677.	1.4	0
130	Phase I Trial of Combination Therapy with 90Y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2006, 108, 4710-4710.	1.4	0
131	Phase I Trial of Combination Therapy with 90Y Ibritumomab Tiuxetan (Zevalin) and Gemcitabine in Patients with Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2007, 110, 4485-4485.	1.4	0
132	CD4 Cell Count of More Than 250/Microl in the Peripheral Blood Is Associated with Improved Overall Survival in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Independent of the aalPI. <i>Blood</i> , 2008, 112, 3775-3775.	1.4	0
133	Immune Function in Follicular Lymphoma (FL): Comparison of Patient with Her Healthy Identical Twin Reveals Enhanced NK Cell Responses in the Patient During Spontaneous Remission [KC1].. <i>Blood</i> , 2009, 114, 5012-5012.	1.4	0
134	Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6. <i>Blood</i> , 2011, 118, 1655-1655.	1.4	0
135	Assessing CD137 (4-1BB) As a Therapeutic Target in B-Cell Neoplasms,. <i>Blood</i> , 2011, 118, 3735-3735.	1.4	0
136	Results of Radiation Therapy for Primary Extranodal Lymphoma of the Head and Neck: A Report of Case Series. <i>Blood</i> , 2011, 118, 4761-4761.	1.4	0
137	Phase I Trial of Combination Therapy with 90y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.. <i>Blood</i> , 2012, 120, 2753-2753.	1.4	0
138	Response-Adapted Therapy for Newly Diagnosed Myeloma. <i>Blood</i> , 2016, 128, 3606-3606.	1.4	0
139	IPI, Comorbidity Index, Hospitalization for Treatment-Related Adverse Events Are Predictors for Outcome in Elderly Diffuse Large B Cell Lymphoma Patients. <i>Blood</i> , 2016, 128, 1860-1860.	1.4	0